Manogepix

Manogepix

SCHEMBL510522

Nc1ncccc1-c1cc(Cc2ccc(COc3ccccn3)cc2)no1

nearest known ligand 0.41

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.41
ALDH1A1 P00352 2/20 0.41
CYP2C19 P33261 2/20 0.41
CYP2D6 P10635 1/20 0.41
RAB9A P51151 5/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
TDP1 Q9NUW8 1/20 0.41
JAK2 O60674 2/20 0.41
ROCK2 O75116 2/20 0.41
PRKACA P17612 2/20 0.41
CDK2 P24941 2/20 0.41
KDR P35968 2/20 0.41
GSK3B P49841 2/20 0.41
AURKB Q96GD4 2/20 0.41
CDC7 O00311 1/20 0.41
MAP4K4 O95819 1/20 0.41
PAK4 O96013 1/20 0.41
PIM1 P11309 1/20 0.41
HIPK2 Q9H2X6 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Manogepix SCHEMBL30518388 1.00 NPC1 (0.41) NPC1ALDH1A1CYP2C19CYP2D6RAB9A
Manogepix SCHEMBL30375321 1.00 NPC1 (0.41) NPC1ALDH1A1CYP2C19CYP2D6RAB9A
Manogepix SCHEMBL1323608 0.99 NPC1 (0.41) NPC1ALDH1A1CYP2C19CYP2D6RAB9A
Manogepix SCHEMBL1323256 0.99 NPC1 (0.41) NPC1ALDH1A1CYP2C19CYP2D6RAB9A
Manogepix SCHEMBL1322997 0.99 NPC1 (0.41) NPC1ALDH1A1CYP2C19CYP2D6RAB9A
Manogepix SCHEMBL1322796 0.99 NPC1 (0.41) NPC1ALDH1A1CYP2C19CYP2D6RAB9A
Manogepix SCHEMBL1323272 0.94 NPC1 (0.37) NPC1ALDH1A1CYP2C19CYP2D6RAB9A
Manogepix SCHEMBL1322795 0.94 NPC1 (0.37) NPC1ALDH1A1CYP2C19CYP2D6RAB9A
Manogepix SCHEMBL1323004 0.92 CDC7 (0.36) NPC1ALDH1A1CYP2C19CYP2D6RAB9A
Manogepix SCHEMBL3468507 0.92 CDC7 (0.38) NPC1ALDH1A1CYP2C19CYP2D6RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210163461-A1 HETEROCYCLE SUBSTITUTED PYRIDINE DERIVATIVE ANTIFUNGAL AGENTS BASILEA PHARMACEUTICA INTERNATIONAL AG, ALLSCHWIL (CH) 2021-06-03 US claimed
EP-3720438-A1 HETEROCYCLE SUBSTITUTED PYRIDINE DERIVATIVE ANTIFUNGAL AGENTS Amplyx Pharmaceuticals, Inc. (US) 2020-10-14 EP claimed
CN-111698989-A Heterocyclic substituted pyridine derivative antifungal agent 安普利克斯制药公司 2020-09-22 CN claimed
WO-2019113542-A1 HETEROCYCLE SUBSTITUTED PYRIDINE DERIVATIVE ANTIFUNGAL AGENTS AMPLYX PHARMACEUTICALS, INC. (US) 2019-06-13 WO claimed
EP-2628738-B1 Heterocyclic substituted pyridine derivatives and antifungal agent containing same EISAI R&D MAN CO LTD (JP) 2014-09-03 EP claimed
US-20130288956-A1 COMBINED PHARMACEUTICAL COMPOSITION AS ANTIFUNGAL AGENT EISAI R&D MANAGEMENT CO., LTD. (JP) 2013-10-31 US claimed
EP-2636409-A1 COMBINED PHARMACEUTICAL COMPOSITION AS ANTIFUNGAL AGENT Eisai R&D Management Co., Ltd. (JP) 2013-09-11 EP claimed
EP-2628738-A1 Heterocyclic substituted pyridine derivatives and antifungal agent containing same Eisai R&D Management Co., Ltd. (JP) 2013-08-21 EP claimed
EP-1944303-B1 PYRIDINE DERIVATIVE SUBSTITUTED BY HETEROCYCLE AND FUNGICIDE CONTAINING THE SAME EISAI R&D MAN CO LTD (JP) 2013-08-21 EP claimed
US-8058444-B2 acid salt of 3-(3-(4-(pyridin-2-yloxymethyl)-benzyl)-isoxazol-5-yl)-pyridin-2-yl amine; inhibiting fungal GPI (glycosylphosphatidyl-inositol) biosynthesis and expression of cell wall proteins; antifungal agents; active against azole-resistant fungi; preventive or therapeutic agent for fungal infections EISAI R&D MANAGEMENT CO., LTD. (JP) 2011-11-15 US claimed
US-7691882-B2 3-(3-(4-(pyridin-2-yloxymethyl)-benzyl)-isoxazol-5-yl)-pyridin-2-ylamine; inhibiting fungal GPI biosynthesis thereby inhibiting expression of cell wall proteins and blocking cell wall assembly while preventing the fungus from attaching to cells EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-04-06 US claimed
EP-2143723-A1 SALT OF HETEROCYCLE-SUBSTITUTED PYRIDINE DERIVATIVE OR CRYSTAL THEREOF Eisai R&D Management Co., Ltd. (JP) 2010-01-13 EP claimed
US-20080275244-A1 HETEROCYCLE-SUBSTITUTED PYRIDINE DERIVATIVE'S SALT OR CRYSTAL THEREOF EISAI R&D MANAGEMENT CO., LTD. (JP) 2008-11-06 US claimed
CN-121914097-A Five-membered heteroaryl compound and application thereof 成都安礼特医药科技有限公司 2026-04-24 CN disclosed
US-20250101012-A1 HETEROCYCLE SUBSTITUTED PYRIDINE DERIVATIVE ANTIFUNGAL AGENTS BASILEA PHARMACEUTICA INTERNATIONAL AG, ALLSCHWIL (CH) 2025-03-27 US disclosed
US-12139479-B2 Heterocycle substituted pyridine derivative antifungal agents BASILEA PHARMACEUTICA INTERNATIONAL AG, ALLSCHWIL (CH) 2024-11-12 US disclosed
EP-1944303-A1 PYRIDINE DERIVATIVE SUBSTITUTED BY HETEROCYCLE AND FUNGICIDE CONTAINING THE SAME Eisai R&D Management Co., Ltd. (JP) 2008-07-16 EP disclosed
US-20070105904-A1 3-(3-(4-(pyridin-2-yloxymethyl)-benzyl)-isoxazol-5-yl)-pyridin-2-ylamine; inhibiting fungal GPI biosynthesis thereby inhibiting expression of cell wall proteins and blocking cell wall assembly while preventing the fungus from attaching to cells EISAI R&D MANAGEMENT CO., LTD. (JP) 2007-05-10 US disclosed
US-20070105904-A1 3-(3-(4-(pyridin-2-yloxymethyl)-benzyl)-isoxazol-5-yl)-pyridin-2-ylamine; inhibiting fungal GPI biosynthesis thereby inhibiting expression of cell wall proteins and blocking cell wall assembly while preventing the fungus from attaching to cells EISAI R&D MANAGEMENT CO., LTD. (JP) 2007-05-10 US disclosed
US-20070105904-A1 3-(3-(4-(pyridin-2-yloxymethyl)-benzyl)-isoxazol-5-yl)-pyridin-2-ylamine; inhibiting fungal GPI biosynthesis thereby inhibiting expression of cell wall proteins and blocking cell wall assembly while preventing the fungus from attaching to cells EISAI R&D MANAGEMENT CO., LTD. (JP) 2007-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250101012-A1 HETEROCYCLE SUBSTITUTED PYRIDINE DERIVATIVE ANTIFUNGAL AGENTS ERG28, DPM1, CYP51A1 NPC1 194/4885ALDH1A1 2033/4885CYP2C19 38/4885
US-20210163461-A1 HETEROCYCLE SUBSTITUTED PYRIDINE DERIVATIVE ANTIFUNGAL AGENTS ERG28, DPM1, CYP51A1 NPC1 194/4885ALDH1A1 2033/4885CYP2C19 38/4885
US-20130288956-A1 COMBINED PHARMACEUTICAL COMPOSITION AS ANTIFUNGAL AGENT DPM1, MTMR1, CHAMP1 NPC1 515/4885ALDH1A1 4390/4885CYP2C19 416/4885
US-12139479-B2 Heterocycle substituted pyridine derivative antifungal agents ERG28, DPM1, CYP51A1 NPC1 194/4885ALDH1A1 2033/4885CYP2C19 38/4885
US-20070105904-A1 3-(3-(4-(pyridin-2-yloxymethyl)-benzyl)-isoxazol-5-yl)-pyridin-2-ylamine; inhibiting fungal GPI biosynthesis thereby inhibiting expression of cell wall proteins and blocking cell wall assembly while preventing the fungus from attaching to cells GPI, ERG28, MAN2A1 NPC1 1201/4885ALDH1A1 3327/4885CYP2C19 707/4885
US-20080275244-A1 HETEROCYCLE-SUBSTITUTED PYRIDINE DERIVATIVE'S SALT OR CRYSTAL THEREOF PDXK, REN, JAK2 NPC1 4237/4885ALDH1A1 2213/4885CYP2C19 698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.